Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis

The investigators are trying to understand the role of specific genes in the function of airway surface cells. The investigators know that there are some common genetic markers that are associated with various lung diseases. However, most people with these genetic markers never develop any evidence of lung disease, so it is not understand how or if these markers play a role in disease. Investigators are asking healthy people to provide three (3) tubes of blood as well as a sample of cells from their nose. Investigators will use the blood sample to provide genetic information (specifically, presence or absence of alleles known to be associated with pulmonary fibrosis). Nose cells from individuals with the genetic markers that investigators are studying will be grown in the the lab to allow investigators to learn more about how the cells respond to various forms of environmental stress, such as exposure to cigarette smoke. The goal of this study is to understand how specific genes affect airway cell function.

Study Overview

• Status: Withdrawn
• Conditions: Healthy; Idiopathic Pulmonary Fibrosis

• Study Type: Observational

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Denver

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

normal healthy volunteers

Description

Inclusion Criteria:

1. Age greater than 18 years of age
2. Ability to provide informed consent
3. Patent bilateral nares

Exclusion Criteria:

1. Significant nasal or sinus disease precluding nasal brushing
2. A history of or ongoing epistaxis (nose-bleeding)
3. Acute upper respiratory illness
4. Ongoing treatment of respiratory or sinus illness with antibiotics
5. Pregnancy
6. Age less than 18 years
7. Infection with human immunodeficiency virus (HIV) or viral hepatitides (Hepatitis B, Hepatitis C)
8. Prior volunteer for the same study
9. Known diagnosis of cystic fibrosis or other ciliary disorder (example: primary ciliar dyskinesia)
10. Treatment with anticoagulants (examples: warfarin/coumadin, low molecular weight heparins, direct thrombin inhibitors such as dabigatran, anti-platelet agents such as P2Y12 inhibitors like clopidogrel and prasugrel, aspirin, ticagrelor, or factor Xa inhibitors such as rivaroxaban)
11. Known thrombocytopenia (example: immune thrombocytopenic purpura)
12. Ongoing chemotherapy
13. Known platelet dysfunction or bleeding diathesis/hemophilia

Study Plan

How is the study designed?

Design Details

• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
in vitro epithelial integrity measured by transepithelial electrical resistance (TEER), reported in ohms	The in vitro epithelial cell culture process will take approximately 4-6 weeks after the cells collected are thawed. (At the time of collection from study subjects, cells will be frozen until the time of thawing and culturing.) The in vitro epithelial process will take 6 weeks to differentiate epithelial monolayers at which time the tests of epithelial integrity can be performed. Study subjects themselves are not being followed.	6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
gene expression (DSP, MUC5B, genes associated with ER Stress), reported as "fold-change" or "CT mean"	Gene expression assays (designed by Taqman/Life Technologies) will be used to examine expression of genes that we believe are associated with pulmonary fibrosis -- specifically, various mucins (MUC5B, MUC5AC, DSP, and numerous genes associated with endoplasmic reticulum (ER) stress). This will be measured on epithelial monolayers derived in vitro from cells collected from study subjects. The differentiation of epithelial monolayers can take 3-6 weeks depending on the vagaries of the cell culture technique.	6 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Epithelial monolayer permeability (protein and cell permeability)	Epithelial monolayer permeability as measured by dextran/protein and neutrophil traffic through monolayer in vitro. This will be measured on epithelial monolayers derived in vitro from cells collected from study subjects. The differentiation of epithelial monolayers can take 3-6 weeks depending on the vagaries of the cell culture technique.	6 weeks.

Collaborators and Investigators

• Sponsor: University of Colorado, Denver
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: David A Schwartz, MD, University of Colorado, Denver

Study record dates

Study Major Dates

• Study Start: July 1, 2015
• Primary Completion (Actual): November 1, 2015
• Study Completion (Actual): November 1, 2015

Study Registration Dates

• First Submitted: March 13, 2014
• First Submitted That Met QC Criteria: July 10, 2014
• First Posted (Estimate): July 11, 2014

Study Record Updates

• Last Update Posted (Estimate): November 30, 2015
• Last Update Submitted That Met QC Criteria: November 25, 2015
• Last Verified: November 1, 2015

More Information

Terms related to this study

• Keywords: Epithelial cell function of cells from individuals with various genotypes
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Fibrosis; Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis
• Other Study ID Numbers: 13-3027; R01HL097163 (U.S. NIH Grant/Contract)